Cargando…

Sequential Use of Second-Generation Tyrosine Kinase Inhibitor Treatment and Intensive Chemotherapy Induced Long-Term Complete Molecular Response in Imatinib-Resistant CML Patient Presenting as a Myeloid Blast Crisis

Myeloid blast crisis of chronic myeloid leukemia (CML-MBC) is rarely seen at presentation and has a poor prognosis. There is no standard therapy for CML-MBC. It is often difficult to distinguish CML-MBC from acute myeloid leukemia expressing the Philadelphia chromosome (Ph+ AML). We present a case i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tsuji, Masaaki, Uchiyama, Tatsuki, Mizumoto, Chisaki, Takeoka, Tomoharu, Tomo, Kenjiro, Ohno, Tatsuharu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2017
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5748101/ https://www.ncbi.nlm.nih.gov/pubmed/29391957 http://dx.doi.org/10.1155/2017/3209305

Ejemplares similares

Concurrent Autoimmune Neutropenia and Idiopathic Thrombocytopenic Purpura Associated with IgG4-related Diease
por: Shimazu, Yayoi, et al.
Publicado: (2018)

Extramedullary blast crisis of secondary CML accompanying marrow fibrosis
por: Go, Jai Hyang, et al.
Publicado: (2012)

Clinical outcomes of second‐generation tyrosine kinase inhibitors versus imatinib in older patients with CML
por: Ono, Takaaki, et al.
Publicado: (2022)

BCR-ABL Mutation-Guided Therapy for CML Blast Crisis: A Case Report
por: Ostendorf, Benjamin N, et al.
Publicado: (2015)

Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy
por: Haaß, Wiltrud, et al.
Publicado: (2015)

Hoxa9 and Hoxa10 induce CML myeloid blast crisis development through activation of Myb expression
por: Negi, Vijay, et al.
Publicado: (2017)

Co-occurrence of CML Blast Crisis and Severe COVID 19 Infection: A Case Report
por: Khaja, Misbahuddin, et al.
Publicado: (2022)

Reply: The long-term response to imatinib treatment of CML
por: Michor, F
Publicado: (2007)

ARE/SUZ12 dual specifically-regulated adenoviral TK/GCV system for CML blast crisis cells
por: Zu, Bailing, et al.
Publicado: (2015)

TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML
por: Valent, Peter, et al.
Publicado: (2017)

Impact of frontline treatment approach on outcomes of myeloid blast phase CML
por: Saxena, Kapil, et al.
Publicado: (2021)

Correction to: ARE/SUZ12 dual specifically-regulated adenoviral TK/GCV system for CML blast crisis cells
por: Zu, Bailing, et al.
Publicado: (2022)

Integrated genomic sequencing in myeloid blast crisis chronic myeloid leukemia (MBC-CML), identified potentially important findings in the context of leukemogenesis model
por: Kazemi-Sefat, Golnaz Ensieh, et al.
Publicado: (2022)

Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study
por: Gemelli, Maria, et al.
Publicado: (2020)

The Combination of Interferon-Alpha and Ponatinib Enables Faster and Deeper Molecular Responses in Patient with De Novo Blast Crisis of CML: Interferon-Alpha May Return as a CML Treatment
por: Hayashi, Kunio, et al.
Publicado: (2021)

MR-1 blocks the megakaryocytic differentiation and transition of CML from chronic phase to blast crisis through MEK dephosphorylation
por: Zhao, W, et al.
Publicado: (2013)

PVR and ICAM-1 on Blast Crisis CML Stem and Progenitor Cells with TKI Resistance Confer Susceptibility to NK Cells
por: Kim, Nayoung, et al.
Publicado: (2020)

Blast Crisis of CML After TKI Discontinuation in a Patient With Previous Stable Deep Molecular Response: Is It Safe to Stop?
por: Papalexandri, Apostolia, et al.
Publicado: (2018)

Deciphering Potential Molecular Signatures to Differentiate Acute Myeloid Leukemia (AML) with BCR::ABL1 from Chronic Myeloid Leukemia (CML) in Blast Crisis
por: Boucher, Lara, et al.
Publicado: (2023)

Coexistence of P190 and P210 BCR/ABL transcripts in chronic myeloid leukemia blast crisis resistant to imatinib
por: Junmei, Zhao, et al.
Publicado: (2015)

MATE1 regulates cellular uptake and sensitivity to imatinib in CML patients
por: Harrach, S, et al.
Publicado: (2016)

Combination of panobinostat with ponatinib synergistically overcomes imatinib‐resistant CML cells
por: Matsuda, Yasufumi, et al.
Publicado: (2016)

Differential cytogenetic profile in advanced chronic myeloid leukemia with sequential lymphoblastic and myeloblastic blast crisis()
por: Calderón-Cabrera, C., et al.
Publicado: (2013)

Author Correction: Integrated genomic sequencing in myeloid blast crisis chronic myeloid leukemia (MBC-CML), identified potentially important findings in the context of leukemogenesis model
por: Kazemi‑Sefat, Golnaz Ensieh, et al.
Publicado: (2023)

Efficacy of Dasatinib in a CML Patient in Blast Crisis with F317L Mutation: A Case Report and Literature Review
por: Morozova, E.V., et al.
Publicado: (2015)

Blast Crisis
por: Kirwin, Margaret, et al.
Publicado: (2020)

The First Reported Case of Allogenic Hematopoietic Stem Cell Transplantation for CML Blast Phase (Monocytic Lineage) in the Tyrosine Kinase Inhibitor Era
por: Yamada, Shinya, et al.
Publicado: (2022)

SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation
por: Giallongo, Cesarina, et al.
Publicado: (2013)

Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib
por: Stella, Stefania, et al.
Publicado: (2019)

Cytopenia among CML Patients on Imatinib in Kenya: Types, Grades, and Time Course
por: McLigeyo, Angela, et al.
Publicado: (2020)

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
por: Hehlmann, R, et al.
Publicado: (2017)

Imatinib-resistant chronic myeloid leukemia (CML): Current concepts on pathogenesis and new emerging pharmacologic approaches
por: Valent, Peter
Publicado: (2007)

Perforation of the Colon During Imatinib Mesylate (Gleevec) Treatment in a Patient with Chronic Myeloid Leukemia (CML)
por: El Jurdi, Najla, et al.
Publicado: (2016)

Discontinuation of Imatinib in Children with Chronic Myeloid Leukemia: A Study from the International Registry of Childhood CML
por: Millot, Frédéric, et al.
Publicado: (2021)

Prognostic Implication of BCR-ABL Fusion Transcript Variants in Chronic Myeloid Leukemia (CML) Treated with Imatinib. A First of Its Kind Study on CML Patients of Kashmir
por: Azad, Niyaz A, et al.
Publicado: (2018)

Ponatinib and other CML Tyrosine Kinase Inhibitors in Thrombosis
por: Zeng, Peng, et al.
Publicado: (2020)

Clonal evolution in a patient with CML detected by FISH precedes imatinib treatment failure
por: Enriquez, Virginia, et al.
Publicado: (2007)

Standard and variant Philadelphia translocation in a CML patient with different sensitivity to imatinib therapy()
por: Aliano, Stefania, et al.
Publicado: (2013)

Inhibition of YAP suppresses CML cell proliferation and enhances efficacy of imatinib in vitro and in vivo
por: Li, Hui, et al.
Publicado: (2016)

Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line
por: Kreutzman, Anna, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_2ufv21g8r6pl08uugfpa0upfm8